Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04GIJ
|
|||
| Drug Name |
Piperazine urea derivative 4
|
|||
| Synonyms |
PMID26936077-Compound-19
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Patented | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Patented | [1] | ||
| Company |
PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26N4O
|
|||
| Canonical SMILES |
C1CN(CCC1CC2=CC=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
|
|||
| InChI |
1S/C21H26N4O/c22-20(23)19-8-6-18(7-9-19)15-24-21(26)25-12-10-17(11-13-25)14-16-4-2-1-3-5-16/h1-9,17H,10-15H2,(H3,22,23)(H,24,26)
|
|||
| InChIKey |
PPLAJHCOIUEWGN-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proteinase activated receptor 2 (PAR2) | Target Info | Antagonist | [1] |
| Target's Patent Info | Proteinase activated receptor 2 (PAR2) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| African trypanosomiasis | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.